Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal

Five Prime, Bristol-Myers Squibb cut $350M immuno-oncology deal.

Mar 18, 2014 at 6:30PM

Five Prime Therapeutics (NASDAQ:FPRX) didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013. But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350 million with Bristol-Myers Squibb (NYSE:BMY) to team up and discover some drugs in the hot field of immuno-oncology.

Bristol and Five Prime will work together to discover, develop, and commercialize immuno-oncology drugs, which are designed to help drive an immune system attack against tumors. Using Five Prime's drug discovery platform, the two will develop therapies that home in on undisclosed targets in two "undisclosed immune checkpoint pathways." Bristol's own experimental antibody, nivolumab, hits PD-1, a target in another such pathway that helps tumors hide from the immune system. The big New York drugmaker wants more potential candidates to use in tandem with its own cancer immunotherapy drugs and is tapping into Five Prime's discovery platform to help find them.

"Five Prime's innovative technology platforms complement our immuno-oncology pipeline and will help expand our understanding of promising new therapeutic options for patients," said Francis Cuss, Bristol's executive vice president and chief scientific officer, in a statement.

Shares of Five Prime jumped about 20 percent in pre-market trading on Monday.

Bristol is paying Five Prime $20 million in cash up front, and another $21 million to buy 4.9 percent of Five Prime's stock at a roughly 30 percent premium over Five Prime's closing share price of $18.75 on Friday. Five prime will also get $9.5 million in research funding spread over the course of the collaboration (Bristol didn't say how long that goes). The biotech could get another $300 million if the candidates discovered in the deal hit various development, regulatory, and sales targets.

The deal is the latest grab in the industrywide free for all to amass as many immuno-oncology assets as possible, and test them in various combinations to try to find the most potent mix. In the past month alone, Novartis acquired Boston-based start-up CoStim Pharmaceuticals and Waltham, MA-based Tesaro inked a wide-ranging antibody discovery deal with AnaptysBio—both with the idea of acquiring more drug candidates in the immuno-oncology field and combining them with other programs. Then, of course, there's Bristol, Merck, and Roche/Genentechwhich all have experimental cancer antibodies that they're reaching all across the industry to test.

Five Prime, meanwhile, has an in-house library of DNA sequences for more than 5,600 human proteins and uses it to try to hunt for previously unknown disease triggers that could be blocked by novel drugs. The company has partnerships in place GlaxoSmithKline and UCB to help discover drugs, and is also using its platform to advance internal drug programs in rheumatoid arthritis and gastric cancer. Still, Five Prime doesn't have any products on the market, and none of its candidates are even in mid-stage studies as of yet.

Five Prime went public at $13 per share in September 2013, pricing right within its $12 to $14 per share range. Shares went south for a bit before steadily rising in late 2013 and early 2014.

Invest In The Next Wave of Healthcare Innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology  behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

This article originally appeared on Xconomy, along with:

Ben Fidler has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers